Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly a year since my last Johnson & Johnson (NYSE: JNJ ) “J&J” article, where I highlighted their Q3 2023 earnings that beat the Street’s projections with $21.4B in revenue, which was up 6.8% year-over-year. At that time, it looked as if th ...